As the U.S. production investments continue to roll in 2025, LTS Lohmann, the German pharmaceutical technology specialist, is joining the table with a deal to boost its CDMO firepower in the U.S.
Like many other contract manufacturing expansions that have been announced in the U.S. in recent months, LTS happens to be charting the move by way of acquisition.
LTS, whose bread-and-butter business happens to revolve around developing and manufacturing drug delivery systems, is indeed paying an undisclosed sum so as to buy the U.S. CDMO Renaissance Lakewood, which in itself happens to specialize in nasal sprays as well as sterile dosage forms.
Due to this move, as LTS grows U.S. footprint, it is going to add the facility at Renaissance to its present roster of production sites across Germany and Israel and also the U.S., where it happens to already operate plants in the areas of West Caldwell, New Jersey, as well as St. Paul, Minnesota, as per an October 12, 2025 press release.
It is well to be noted that Renaissance was founded in 1979 and happens to be headquartered in Lakewood, New Jersey, where its production campus is also located. The contractor happens to manufacture the unit-dose and bi-dose as well as multi-dose nasal sprays, along with small-volume parenteral fill-finish vials, explained LTS in its release. Renaissance also goes on to boast the R&D formulation development and also spray characterization capacities by way of its labs.
Apparently, Renaissance is joining the fold with almost 500 employees in tow, confirmed the LTS, which noted that the acquisition is indeed going to expand its drug delivery repertoire and at the same time also solidify its position when it comes to the CDMO market.
All put together, Renaissance functions across over 310,000 square feet of manufacturing and laboratory space, as well as support infrastructure, throughout its New Jersey campus, as per the company website.
According to chief executive of LTS, Bas van Buijtenen, this acquisition is indeed going to mark a significant step in their strategy to go ahead and expand their CDMO capabilities and at the same time also strengthen their position as a global leader when it comes to innovative drug delivery solutions. The expertise of Renaissance when it comes to nasal sprays and also sterile dosage forms perfectly happens to complement their existing portfolio and is going to help them to offer even better value to their partners and, of course, the patients across the world.
Apparently, LTS has not disclosed the financial terms of the deal as yet, and the company expects the Renaissance acquisition to get closed before the end of November 2025.
It is well to be noted that as LTS grows U.S. footprint, the news of the acquisition happens to come as U.S. manufacturing announcements continue to come in from all over the industry. The fact is that much of the domestic production push has been fueled by the threat of pharmaceutical import tariffs as per the Trump administration. In the scenario of large, branded drugmakers, such import duty concerns have also spurred large investments within the greenfield sites across the U.S.
When it comes to the CDMOs as well as producers in terms of generic and biosimilar drugs, however, M&A has gone on to be frequently proven as a popular route so as to bloat up the U.S. manufacturing in 2025.
Recently, OXB, which was formerly known as Oxford Biomedica, which happens to be the U.K.-based cell and gene therapy manufacturer, went on to lay out 4.5 million so as to get its hands on a commercial-scale drug factory that was based in North Carolina from National Resilience, the fellow CDMO.
And it was late in September, 2025, that Laboratorios Farmacéuticos Rovi, the Spanish contractor, better known colloquially as Rovi, went ahead and picked up a production plant in Phoenix, Arizona, from Bristol Myers Squibb. The BMS site, which is in question here, happens to be equipped to produce potent cytotoxic products, obesity drugs, vaccines, biosimilars, and monoclonal antibodies, as well as antibody-drug conjugates.
When it comes to the biosimilar front, Celltrion from Korea has adopted a very similar tactic and has agreed to pay 460 billion Korean won, or $330 million, for an Eli Lilly drug substance plant based out of New Jersey’s Branchburg, which, as per its claims, has completely eliminated all the potential future tariff risks that are related to its products across the U.S. market.
Meanwhile, Ypsomed, the fellow drug delivery specialist that has made a name for itself in terms of designing and manufacturing auto-injectors for liquid drugs, went on to take an alternate approach when it revealed its plans to spend 200 million Swiss francs, which is equivalent to $248 million, so as to build its first U.S. plant based out of North Carolina’s Holly Springs.
It is worth noting that the outpouring of life sciences investment dollars in the U.S. goes on to follow after an announcement from President Donald Trump in late September 2025, which suggested that companies are going to face a 100% import tariff when it comes to any branded pharma product that is going to be shipped from overseas to the U.S. unless these companies happen to be actively building production facilities across the U.S.
